MiNK Therapeutics shared a post on LinkedIn:
“MiNK Therapeutics proudly welcomes Terese C. Hammond, MD as our new Head of Inflammatory and Pulmonary Diseases. A nationally recognized leader in pulmonary and critical care, Dr. Hammond brings decades of experience advancing transformative therapies for patients facing severe immune and respiratory challenges.
She joins MiNK at a pivotal moment as we prepare for:
– A grant-supported clinical trial in GvHD
– A planned pivotal trial in severe pulmonary disease
– Continued expansion of our iNKT platform with real-world insights from the clinic
Her leadership and deep clinical expertise will accelerate our mission to bring next-generation immune reconstitution therapies to patients in critical need.
Read the full announcement.”
More Posts Featuring MiNK Therapeutic.